NasdaqCM:NEOHealthcare
NeoGenomics (NEO) FY 2025 Revenue Growth With Ongoing Losses Tests Bullish Narratives
NeoGenomics (NEO) FY 2025 Financial Results
NeoGenomics (NEO) has wrapped up FY 2025 with Q4 revenue of US$190.2 million and a basic EPS loss of US$0.08, setting the tone for a year where the top line grew while the bottom line stayed in the red. Over recent quarters, the company has seen revenue move from US$168.0 million in Q1 2025 to US$190.2 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$0.20 to a loss of US$0.35. On a trailing 12 month basis, EPS sits at a...